Clinical utility of dabigatran in United Arab Emirates: A pharmacovigilance study

Abdulla Shehab, Asim A. Elnour, Adel Sadik, Mahmoud Abu Mandil, Ali AlShamsi, Aesha Al Suwaidi, Akshayasrikanth Bhagavathula, Pinar Erkekoglu, Farah Hamad, Saif K. Al Nuaimi

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To provide early data regarding clinical utility of dabigatran in Al-Ain, United Arab Emirates (UAE). Methods: This was an ethics approved retrospective cross sectional study. We retrieved a total of 76 patients who were using dabigatran from September to December 2014 in the Cardiology Clinic at Al-Ain Hospital, Al-Ain, UAE. The primary analysis was designed to test the frequency of bleeding events (rate) with dabigatran 75, 110, and 150 mg. Results: The mean age ± standard deviation of cohort was 67.9 ± 1.5 years (range; 29-98 years), composed of males (52.6%) with mean age of 66.3 ± 1.7 years, and females (47.4%) with mean age of 69.6 ± 1.1 years. The highest age group was those between 61-80 years (60.5%). Most comprised the age strata of ≤75 years (73.7%). The main indication for dabigatran use was atrial fibrillation. The rate of bleeding with dabigatran was 18/76 (23.7%), and melena was the leading cause of bleeding 8/76 (10.7%). The hospitalization rate was 67.1%, dabigatran withdrawal rate was 0.01%, and mortality rate was 6.5%. The cohort had exhibited incidences of minor bleeding with one fatal major bleeding, high co-morbidities, admission, and readmission, which was not directly linked to dabigatran. We did not identify any relation of death due to dabigatran. Conclusion: Dabigatran is a suitable alternative to warfarin obviating the need for repetitive international normalized ratio monitoring, however, it may need plasma drug monitoring.

Original languageEnglish
Pages (from-to)1290-1298
Number of pages9
JournalSaudi Medical Journal
Volume36
Issue number11
DOIs
Publication statusPublished - Nov 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Clinical utility of dabigatran in United Arab Emirates: A pharmacovigilance study'. Together they form a unique fingerprint.

Cite this